| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Upswing helps you #getbackintheswing of things. We help athletes identify injuries and find the best path to recovery.
Taris Biomedical is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Steadman Hawkins Sports Medicine Foundation is a Vail, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Passavant Area Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Passavant Area Hospital is based in Jacksonville, IL. You can find more information on Passavant Area Hospital at www.passavanthospital.com